Balboa-Barreiro, V., Pértega-Díaz, S., García-Rodríguez, T., González-Martín, C., Pardeiro-Pértega, R., Yáñez-González-Dopeso, L., & Seoane-Pillado, T. (2024). Colorectal cancer recurrence and its impact on survival after curative surgery: An analysis based on multistate models. Digestive and Liver Disease, 56(7), 1229–1236.

Bittla, P., Kaur, S., Sojitra, V., Zahra, A., Hutchinson, J., Folawemi, O., & Khan, S. (2023). Exploring circulating tumor DNA (CtDNA) and its role in early detection of cancer: A systematic review. Cureus, 15(9), e45784.

Boute, T. C., Swartjes, H., Greuter, M. J. E., Elferink, M. A. G., van Eekelen, R., Vink, G. R., de Wilt, J. H. W., & Coupé, V. M. H. (2024). Cumulative incidence, risk factors, and overall survival of disease recurrence after curative resection of stage II–III colorectal cancer: A population-based study. Cancer Research Communications, 4(2), 607–616.

Cescon, D. W., Bratman, S. V., Chan, S. M., & Siu, L. L. (2020). Circulating tumor DNA and liquid biopsy in oncology. Nature Cancer, 1(3), 276–290.

Chen, G., Peng, J., Xiao, Q., Wu, H. X., Wu, X., Wang, F., Li, L., Ding, P., Zhao, Q., Li, Y., Wang, D., Shao, Y., Bao, H., Pan, Z., Ding, K. F., Cai, S., Wang, F., & Xu, R. H. (2021). Postoperative circulating tumor DNA as markers of recurrence risk in stages II to III colorectal cancer. Journal of Hematology and Oncology, 14(1), 80.

Chen, X., Zhang, T., Su, W., Dou, Z., Zhao, D., Jin, X., Lei, H., Wang, J., Xie, X., Cheng, B., Li, Q., Zhang, H., & Di, C. (2022). Mutant p53 in cancer: From molecular mechanism to therapeutic modulation. Cell Death and Disease, 13(11), 974.

Chung, D. C., Gray, D. M. 2nd, Singh, H., Issaka, R. B., Raymond, V. M., Eagle, C., Hu, S., Chudova, D. I., Talasaz, A., Greenson, J. K., Sinicrope, F. A., Gupta, S., & Grady, W. M. (2024). A cell-free DNA blood-based test for colorectal cancer screening. The New England Journal of Medicine, 390(11), 973–983.

Ciombor, K. K., Strickler, J. H., Bekaii-Saab, T. S., & Yaeger, R. (2022). BRAF-mutated advanced colorectal cancer: A rapidly changing therapeutic landscape. Journal of Clinical Oncology, 40, 2706–2715.

Feroz, W., & Sheikh, A. M. A. (2020). Exploring the multiple roles of guardian of the genome: P53. Egyptian Journal of Medical Human Genetics, 21, 49.

Hruzyeva, T. S., Lytvynova, L. O., Grechishkina, N. V., Zamkevych, V. B., Donik, O. M., & Inshakova, H. V. (2018). Social medicine, public health. National Medical University named after O. O. Bohomolets, Kyiv.

Khakoo, S., Carter, P. D., Brown, G., Valeri, N., Picchia, S., Bali, M. A., Shaikh, R., Jones, T., Begum, R., Rana, I., Wotherspoon, A., Terlizzo, M., von Loga, K., Kalaitzaki, E., Saffery, C., Watkins, D., Tait, D., Chau, I., Starling, N., Hubank, M., & Cunningham, D. (2020). MRI tumor regression grade and circulating tumor DNA as complementary tools to assess response and guide therapy adaptation in rectal cancer. Clinical Cancer Research, 26(1), 183–192.

Kopetz, S., Murphy, D. A., Pu, J., Ciardiello, F., Desai, J., Van Cutsem, E., Wasan, H. S., Yoshino, T., Saffari, H., Zhang, X., Hamilton, P., Xie, T., Yaeger, R., & Tabernero, J. (2024). Molecular profiling of BRAF-V600E-mutant metastatic colorectal cancer in the phase 3 BEACON CRC trial. Nature Medicine, 30(11), 3261–3271.

Li, Q. H., Wang, Y. Z., Tu, J., Liu, C. W., Yuan, Y. J., Lin, R., He, W. L., Cai, S. R., He, Y. L., & Ye, J. N. (2020). Anti-EGFR therapy in metastatic colorectal cancer: Mechanisms and potential regimens of drug resistance. Gastroenterology Report, 8(3), 179–191.

Maji, L., Teli, G., Raghavendra, N. M., Sengupta, S., Pal, R., Ghara, A., & Matada, G. S. P. (2023). An updated literature on BRAF inhibitors (2018–2023). Molecular Diversity, 28(4), 2689–2730.

Mas, L., Bachet, J. B., Taly, V., Bouché, O., Taieb, J., Cohen, R., Meurisse, A., Normand, C., Gornet, J. M., Artru, P., Louafi, S., Thirot-Bidault, A., Baumgaertner, I., Coriat, R., Tougeron, D., Lecomte, T., Mary, F., Aparicio, T., Marthey, L., Blons, H., … Laurent-Puig, P. (2019). BRAF mutation status in circulating tumor DNA from patients with metastatic colorectal cancer: Extended mutation analysis from the AGEO RASANC study. Cancers, 11(7), 998.

Moskalenko, Y. V., Vynnychenko, O. I., Sulaieva, O. M., & Moskalenko, R. A. (2023). The role of next-generation sequencing in lung cancer diagnosis. Eastern Ukrainian Medical Journal, 11(3), 214–223.

Najafi, S., Majidpoor, J., & Mortezaee, K. (2024). Liquid biopsy in colorectal cancer. Clinica Chimica Acta, 553, 117674.

Nakamura, Y., Watanabe, J., Akazawa, N., Hirata, K., Kataoka, K., Yokota, M., Kato, K., Kotaka, M., Kagawa, Y., Yeh, K. H., Mishima, S., Yukami, H., Ando, K., Miyo, M., Misumi, T., Yamazaki, K., Ebi, H., Okita, K., Hamabe, A., Sokuoka, H., & Oki, E. (2024). ctDNA-based molecular residual disease and survival in resectable colorectal cancer. Nature Medicine, 30(11), 3272–3283.

Nikanjam, M., Kato, S., & Kurzrock, R. (2022). Liquid biopsy: Current technology and clinical applications. Journal of Hematology and Oncology, 15, 131.

Ogunwobi, O. O., Mahmood, F., & Akingboye, A. (2020). Biomarkers in colorectal cancer: Current research and future prospects. International Journal of Molecular Sciences, 21(15), 5311.

Oh, H. H., & Joo, Y. E. (2020). Novel biomarkers for the diagnosis and prognosis of colorectal cancer. Intestinal Research, 18(2), 168–183.

Scarlotta, M., Simsek, C., & Kim, A. K. (2019). Liquid biopsy in solid malignancy. Genetic Testing and Molecular Biomarkers, 23(4), 284–296.

Sclafani, F., Wilson, S. H., Cunningham, D., Gonzalez De Castro, D., Kalaitzaki, E., Begum, R., Wotherspoon, A., Capdevila, J., Glimelius, B., Roselló, S., Thomas, J., Tait, D., Brown, G., Oates, J., & Chau, I. (2020). Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients. International Journal of Cancer, 146(1), 94–102.

Śmiech, M., Leszczyński, P., Kono, H., Wardell, C., & Taniguchi, H. (2020). Emerging BRAF mutations in cancer progression and their possible effects on transcriptional networks. Genes, 11(11), 1342.

Suzuki, T., Suzuki, T., Yoshimura, Y., Yahata, M., Yew, P. Y., Nakamura, T., Nakamura, Y., Park, J. H., & Matsuo, R. (2020). Detection of circulating tumor DNA in patients of operative colorectal and gastric cancers. Oncotarget, 11(34), 3198–3207.

Tao, X. Y., Li, Q. Q., & Zeng, Y. (2024). Clinical application of liquid biopsy in colorectal cancer: Detection, prediction, and treatment monitoring. Molecular Cancer, 23(1), 145.

Testa, U., Castelli, G., & Pelosi, E. (2020). Genetic alterations of metastatic colorectal cancer. Biomedicines, 8, 414.

Tsai, T. J., Syu, K. J., Huang, X. Y., Liu, Y. S., Chen, C. W., Wu, Y. H., Lin, C. M., & Chang, Y. Y. (2024). Identifying timing and risk factors for early recurrence of resectable rectal cancer: A single center retrospective study. World Journal of Gastrointestinal Surgery, 16(9), 2842–2852.

Uprety, N., & Adjei, A. A. (2020). KRAS: From undruggable to a druggable cancer target. Cancer Treatment Reviews, 89, 102070.

Vacante, M., Ciuni, R., Basile, F., & Biondi, A. (2020). The liquid biopsy in the management of colorectal cancer: An overview. Biomedicines, 8(9), 308.

Vanhaesebroeck, B., Perry, M. W. D., Brown, J. R., André, F., & Okkenhaug, K. (2021). PI3K inhibitors are finally coming of age. Nature reviews. Drug Discovery, 20(10), 741–769.

Voutsadakis, I. A. (2021). The landscape of PIK3CA mutations in colorectal cancer. Clinical Colorectal Cancer, 20(3), 201–215.

Zheng, Z., Wang, X., Huang, Y., Lu, X., Huang, Z., & Chi, P. (2020). Defining and predicting early recurrence in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. European Journal of Surgical Oncology, 46(11), 2057–2063.

Zhou, H., Zhu, L., Song, J., Wang, G., Li, P., Li, W., Luo, P., Sun, X., Wu, J., Liu, Y., Zhu, S., & Zhang, Y. (2022). Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Molecular Cancer, 21(1), 86.

Zhou, J., Ji, Q., & Li, Q. (2021). Resistance to anti-EGFR therapies in metastatic colorectal cancer: Underlying mechanisms and reversal strategies. Journal of Experimental and Clinical Cancer Research, 40, 328.

Zhuang, Y., Wang, H., Jiang, D., Li, Y., Feng, L., Tian, C., Pu, M., Wang, X., Zhang, J., Hu, Y., & Liu, P. (2021). Multi gene mutation signatures in colorectal cancer patients: Predict for the diagnosis, pathological classification, staging and prognosis. BMC Cancer, 21(1), 380.